Coming to the phase III clinical trials, the primary outcome measures of niraparib alone and in comparison with physician’s choice have been under evaluation for maintenance therapy of advanced ovarian cancer patients following a response to front line platinum based therapy and human epidermal growth factor receptor 2 negative (HER2-), gBRCA mut-positive breast cancer patients, respectively(Table 5) [62]. This evidence concerns the gene ERBB2 and ovarian carcinoma.